Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company developing novel therapies for life-threatening immune and thrombotic conditions. The company's lead product candidate, CAD-1005, is a first-in-class selective 12-lipoxygenase (12-LOX) inhibitor being developed for the treatment and prevention of heparin-induced thrombocytopenia (HIT). CAD-1005 holds Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration, as well as orphan drug status from the European Medicines Agency. The company's broader pipeline includes tecarfarin, an oral vitamin K antagonist designed for patients with end-stage kidney disease or left ventricular assist devices, and frunexian, a parenteral Factor XIa inhibitor intended for acute and critical care hospital settings. In December 2025, Cadrenal acquired the 12-LOX platform assets, including CAD-1005 and the CAD-2000 series, from Veralox Therapeutics. The company also holds an exclusive license from Old Dominion University for the development and commercialization of specific 12-LOX inhibitor derivatives.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage cadrenal.com
Sector Healthcare IR page cadrenal.com/investors
Tags
anticoagulation, thrombosis, heparin-induced thrombocytopenia, 12-lipoxygenase inhibitors, factor xi inhibitors, vitamin k antagonists, immune-mediated disorders, critical care, cardiovascular disease, nephrology, CAD-1005, tecarfarin, frunexian, CAD-2000, VLX-1005, VLX-2000, Veralox Therapeutics, Old Dominion University
Press page cadrenal.com/press-releases

Metrics

Valuation  
Market cap $ 4.383M
Market cap (USD) $ 4.383M
P/E -0.28
PEG —
P/BV 1.51
P/S —
P/OCF -0.45
P/FCF -0.35
Dividend yield —
Turnover / mcap —
Returns  
ROE -260.1%
ROI -483.3%
ROIC -368.6%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock —
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 4
Quality score -81.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022
Assets 4.327M 10.124M 8.519M 778.174K
Net profit -13.237M -10.651M -8.357M -6.714M
Free cash flow -12.607M -7.364M -3.534M -1.207M

Figure FY 2025 FY 2024 FY 2023 FY 2022
Share price 6.78 14.49 0.74 —
Price performance 12m -0.53 18.58 — —

Filed figures

Figure Mar 2008 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — 597,068 — — —
Lease liabilities (USD) — 43,638 21,350 — —
Cash and deposits (USD) — 32,586 8.4M 10M 4.01M
Right-of-use assets (USD) — 43,578 20,998 — —
Net debt (borrowings + leases - cash) (USD) — 608,120 — — —
Cash flow detail
Operating cash flow (USD) — -1.2M -3.53M -7.36M -12.6M
Purchases of property, plant and equipment (USD) — -2,279 -3,254 -6,537 -5,104
Change in payables (cash effect) (USD) — 404,897 -237,578 1.34M -851,805
Share-based compensation (USD) — 928,049 710,381 1.42M 1.94M
Free cash flow (OCF - PPE - intangibles) (USD) — -1.21M -3.53M -7.36M -12.6M
Income detail
Research and development expense (USD) 200,000 136,802 4.08M 4.21M 4.1M
Total comprehensive income (USD) — -6.71M — — —
Reported Mar 30, 2023 Mar 30, 2023 Mar 11, 2024 Mar 13, 2025 Mar 31, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

  • Pipeline has reached clinical and regulatory maturity following recent alignment with FDA on Phase 3 development pathway for CAD-1005
  • Cadrenal has received strong interest from potential strategic partners
  • Cadrenal will explore all strategic alternatives including corporate partnerships and other strategic transactions

PONTE VEDRA, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) (“Cadrenal” or the “Company”), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced that its Board of Directors has initiated a formal strategic process to evaluate opportunities to maximize the value of the Company and its asset portfolio.

The initiative builds on Cadrenal’s ongoing strategic partnering discussions and will evaluate a broad range of potential transactions involving the Company and its clinical- and development-stage programs, including CAD-1005, tecarfarin, frunexian, and CAD-2000, the Company’s second-generation 12-LOX platform. Potential opportunities may include licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions, business combinations, or other strategic transactions.

Cadrenal has engaged Tungsten Advisors as the Company’s exclusive strategic financial advisor in connection with the process.

“Our pipeline has reached critical clinical and regulatory maturity, anchored by our recent alignment with the FDA on the Phase 3 development pathway for CAD-1005,” said Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics. “Having received strong interest from potential strategic partners, we believe a formal strategic process provides the appropriate framework to evaluate opportunities across our portfolio and determine the paths that can maximize value for our shareholders while advancing these programs for patients.”

There can be no assurance that the strategic process will result in any transaction or other strategic outcome. Cadrenal does not intend to provide updates on the process unless and until its Board of Directors approves a specific transaction or course of action, or the Company otherwise determines that disclosure is appropriate or required.

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The Company’s portfolio comprises clinical- and development-stage programs addressing significant unmet needs in critical care cardiology and orphan cardiovascular conditions.

CAD-1005 is a first-in-class 12-lipoxygenase (12-LOX) inhibitor in development to treat heparin-induced thrombocytopenia (HIT), a serious immune-mediated thrombotic disorder. CAD-1005 is designed to selectively inhibit 12-LOX, a pathway involved in platelet immune activation and thrombo-inflammatory signaling in HIT. The program has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration and orphan drug status from the European Medicines Agency. Cadrenal has received FDA feedback on the pathway for a Phase 3 registration study of CAD-1005 in HIT.

Tecarfarin is a Phase 3-ready oral vitamin K antagonist under development for patients requiring chronic anticoagulation, including those with end-stage kidney disease, atrial fibrillation, and implanted left ventricular assist devices. Tecarfarin has received FDA Orphan Drug and Fast Track designations for certain indications.

Frunexian is an investigational parenteral small-molecule Factor XIa inhibitor under development for acute and critical care settings, including major cardiac surgery.

CAD-2000 is a preclinical, next-generation, orally bioavailable 12-lipoxygenase (12-LOX) inhibitor under development as an outpatient Immunology & Inflammation (I&I) platform. CAD-2000 targets adipo-inflammatory signaling and systemic lipid-driven inflammation to address chronic metabolic and cardiorenal disorders. Positioned as an oral follow-on companion to CAD-1005, the asset is optimized for broad, large-market chronic inflammatory indications, including obesity-driven systemic inflammation, metabolic-associated steatohepatitis (MASH), and chronic cardiorenal diseases. It offers potential therapeutic synergy when combined with existing blockbuster metabolic regimens. For more information, please visit www.cadrenal.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements include, among other things, statements regarding the Company’s strategic process; the potential timing, structure, benefits and outcome of that process; the possibility of any licensing transaction, asset sale, partnership, business combination or other strategic transaction; the clinical development, regulatory approval and commercialization of CAD-1005, tecarfarin, frunexian, CAD-2000 and the Company’s other programs; and the potential benefits and market opportunities associated with the Company’s product candidates.

Forward-looking statements may be identified by words such as “anticipate,” “believe,” “could,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied.

These risks and uncertainties include, without limitation, the possibility that the strategic process may not result in a transaction; the Company’s ability to identify, negotiate and complete any strategic transaction on acceptable terms or at all; potential disruption to the Company’s business during the strategic process; the Company’s need for additional capital and ability to obtain financing on acceptable terms; risks associated with clinical development and regulatory approval; the Company’s ability to develop and commercialize its product candidates; the Company’s ability to maintain the listing of its common stock on The Nasdaq Capital Market; and the other risks described under the heading “Risk Factors” in Cadrenal’s filings with the Securities and Exchange Commission.

Readers are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements speak only as of the date of this press release, and Cadrenal undertakes no obligation to update them except as required by applicable law.

Amendment to 2022 Successor Equity Incentive Plan

On September 24, 2026, Cadrenal Therapeutics, Inc. (the “Company”), held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). At the 2026 Annual Meeting, the Company’s stockholders approved an amendment (the “Amendment No. 2”) to the Company’s 2022 Successor Equity Incentive Plan, as amended (the “2022 Plan”), to increase the number of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), that will be available for awards under the 2022 Plan by 323,542 shares to 1,000,000 shares. A description of the Amendment No. 2 is set forth in the Company’s definitive proxy statement on Schedule 14A for the 2026 Annual Meeting (the “Proxy Statement”), which was filed with the Securities and Exchange Commission on August 3, 2026, in the section entitled “PROPOSAL 3: PLAN AMENDMENT PROPOSAL,” which is incorporated herein by reference. The description of Amendment No. 2 included in the Proxy Statement is not intended to be complete and is qualified in its entirety by reference to the full text of the Amendment No.

PONTE VEDRA, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, announced that CEO Quang X. Pham will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.

Company Webcast

The webcast presentation will take place at 10:15 a.m. ET on Tuesday, September 29, 2026. The webcast can be accessed by visiting the conference website at https://lythampartners.com/fall2026/ or directly at https://app.webinar.net/45v0RKgRmKD. The webcast will also be available for replay following the event.

1×1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×[email protected] or register for the event at https://lythampartners.com/fall2026invreg/.

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions. The Company’s pipeline includes CAD-1005, tecarfarin, and frunexian. CAD-1005 is a novel investigational therapeutic in development for the treatment of heparin-induced thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). CAD-1005 is designed to selectively inhibit 12-lipoxygenase (12-LOX), an enzyme central to platelet immune activation and thrombo-inflammatory signaling in HIT. CAD-1005 is intended to be used alongside existing standards of care and is being developed to address the underlying biological mechanisms that drive disease progression. CAD-1005 has an Orphan Drug Designation (“ODD”) from the U.S. Food and Drug Administration (“FDA”) for prophylaxis of thrombosis in patients with HIT, FDA Fast Track designation for the treatment and prevention of HIT, and an orphan designation from the European Medicines Agency for the treatment of platelet-activating factor 4 disorders. Second-generation 12-LOX oral therapeutics (CAD-2000) are also in development for chronic indications.

The Company’s broader pipeline includes tecarfarin, a late-stage oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease and atrial fibrillation, those with left ventricular assist devices, and potentially those with Kawasaki disease (KD), an acute, self-limited, febrile illness that primarily affects children under 5 years old and is the leading cause of acquired heart disease in developed countries. The Company recently submitted a request to the FDA for Rare Pediatric Disease Designation (RPDD) for tecarfarin for “Prevention of the Formation of Life-Threatening Blood Clots Inside Coronary Artery Aneurysms in Children with Kawasaki Disease”. Tecarfarin has also received Orphan Drug and Fast Track designations from the FDA.

Prompts

Cadrenal Therapeutics, Inc. (ticker CVKD), listed in United States.

ETFs Holding Cadrenal Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
DFSU 0.00% 914 $ 1,380.14 Nov 12, 2026